CapEdge
Loading...
Advanced
What's new? Log in Free sign up
  • Home
  • Sectors & IndustriesSectors
  • Earnings
  • IPOs
  • SPACs
  • Transcripts
  • Insider
  • Institutional
  • Crypto
  • Screeners
  • Reddit
  • Splits
  • OBIO Dashboard
  • Financials
  • Filings
  • ETFs
  • Insider
  • Institutional
  • Shorts
  • News
  • Reddit

Orchestra BioMed (OBIO)

Company Profile
Orchestra BioMed is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading medical device companies. Orchestra BioMed’s partnership-enabled business model focuses on forging strategic collaborations with leading medical device companies to drive successful global commercialization of products it develops. Orchestra BioMed’s flagship product candidates include BackBeat Cardiac Neuromodulation Therapy™ (CNT™) for the treatment of hypertension, a significant risk factor for death worldwide, and Virtue® Sirolimus AngioInfusion™ Balloon (SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Orchestra BioMed has a strategic collaboration with Medtronic, one of the largest medical device companies in the world, for development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients, and a strategic partnership with Terumo Corporation, a global leader in medical technology, for development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed has additional product candidates and plans to potentially expand its product pipeline through acquisitions, strategic collaborations, licensing, and organic development. For further information about Orchestra BioMed, please visit www.orchestrabiomed.com.
Orchestra BioMed logo

Company profile

Ticker
OBIO, HSAQ
Exchange
NASDAQ
Employees
Incorporated
Delaware
Location
Pennsylvania
Fiscal year end
Dec 31
Industry (SIC)
Surgical & Medical Instruments & Apparatus
3M • Baxter International • Boston Scientific • Stryker • Becton, Dickinson And • Teleflex • Resmed • Haemonetics • Hill-Rom • Nuvasive ...
Former names
Health Sciences Acquisitions Corp 2
SEC CIK
0001814114
Corporate docs
Articles of Incorporation & Bylaws
Underwriting Agreements
Plans of Reorganization
Indentures
Material Contracts & Credit Agreements
Subsidiaries Lists
Subsidiaries
HSAC Olympus Merger Sub, Inc. ...

OBIO stock data

Latest filings (excl ownership)
View all
8-K
Entry into a Material Definitive Agreement
31 Jan 23
10-K
2022 FY
Annual report
25 Jan 23
425
Business combination disclosure
25 Jan 23
8-K
Departure of Directors or Certain Officers
25 Jan 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
24 Jan 23
8-K
Other Events
23 Jan 23
425
Business combination disclosure
10 Jan 23
8-K
Material Modifications to Rights of Security Holders
21 Dec 22
EFFECT
Notice of effectiveness
19 Dec 22
424B3
Prospectus supplement
16 Dec 22
Latest ownership filings
View all
4
Change in insider ownership
1 Feb 23
3
Initial statement of insider ownership
1 Feb 23
4
Yuval Mika
30 Jan 23
4
Michael Kaswan
30 Jan 23
4
Connealy Pamela Yanchik
30 Jan 23
4
Joshua Aiello
30 Jan 23
4
Jason Aryeh
30 Jan 23
4
Eric S Fain
30 Jan 23
4
ERIC A MD ROSE
30 Jan 23
4
David P Hochman
30 Jan 23

Financial summary

Financial statements Chart OBIO financial data
Quarter (USD) Dec 22 Sep 22 Jun 22 Mar 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 22 Dec 21 Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 175.16 k 175.16 k 175.16 k 175.16 k 175.16 k
Cash burn (monthly) 186.69 k 131.61 k 292.24 k 256.69 k 89.21 k
Cash used (since last report) 205.28 k 144.72 k 321.35 k 282.26 k 98.09 k
Cash remaining -30.12 k 30.44 k -146.19 k -107.09 k 77.07 k
Runway (months of cash) -0.2 0.2 -0.5 -0.4 0.9

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2022

OBIO institutional ownership history Ownership history
89.7% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 24 62 -61.3%
Opened positions 4 9 -55.6%
Closed positions 42 6 +600.0%
Increased positions 2 16 -87.5%
Reduced positions 9 5 +80.0%
13F shares Current Prev Q Change
Total value 112.26 mm 197.34 mm -43.1%
Total shares 10.06 mm 18.56 mm -45.8%
Total puts 0.00 0.00
Total calls 0.00 0.00
Total put/call ratio – – –
Largest owners Shares Value Change
HSAC 2 4.36 mm $55.86 mm 0.0%
RTW Investments 1.00 mm $9.90 mm NEW
BLK Blackrock 790.44 k $7.83 mm -0.6%
T. Rowe Price 724.57 k $7.18 mm -0.4%
Ra Capital Management 610.28 k $6.04 mm -2.4%
Boxer Capital 400.00 k $3.96 mm 0.0%
EcoR1 Capital 400.00 k $3.96 mm 0.0%
Avidity Partners Management 400.00 k $3.96 mm 0.0%
Tang Capital Management 392.50 k $3.89 mm NEW
Sio Capital Management 250.00 k $2.48 mm 0.0%
Largest transactions Shares Bought/sold Change
RTW Investments 1.00 mm +1.00 mm NEW
D. E. Shaw & Co. 0.00 -938.39 k EXIT
Adage Capital Partners GP, L.L.C. 0.00 -800.00 k EXIT
Saba Capital Management 0.00 -737.49 k EXIT
Amitell Capital Pte 0.00 -600.14 k EXIT
Sculptor Capital 0.00 -542.85 k EXIT
Centiva Capital 0.00 -484.33 k EXIT
WRB W.R. Berkley 19.90 k -472.31 k -96.0%
Radcliffe Capital Management 0.00 -407.56 k EXIT
Tang Capital Management 392.50 k +392.50 k NEW
Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

OBIO insider ownership history Insider history
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
30 Jan 23 Medtronic Common Stock Buy Acquire P Yes No 9.281 6,835 63.44 k 4,999,423
26 Jan 23 Geoffrey Wade Smith Common Stock Grant Acquire A Yes No 0 256,623 0.00 256,623
26 Jan 23 Geoffrey Wade Smith Common Stock Grant Acquire A Yes No 0 1,049,224 0.00 1,049,224
26 Jan 23 Geoffrey Wade Smith Common Stock Grant Acquire A Yes No 0 201,319 0.00 201,319
26 Jan 23 Geoffrey Wade Smith Common Stock Grant Acquire A No No 0 3,488 0.00 3,488
26 Jan 23 Geoffrey Wade Smith Stock Options Common Stock Grant Acquire A No No 10 23,250 232.50 k 23,250
26 Jan 23 Geoffrey Wade Smith Stock Options Common Stock Grant Acquire A No No 4.3011 6,975 30.00 k 6,975
26 Jan 23 Geoffrey Wade Smith Stock Options Common Stock Grant Acquire A No No 4.3011 18,600 80.00 k 18,600
26 Jan 23 Geoffrey Wade Smith Warrants Common Stock Grant Acquire A Yes No 21.5054 519 11.16 k 519
26 Jan 23 Geoffrey Wade Smith Warrants Common Stock Grant Acquire A Yes No 21.5054 136,097 2.93 mm 136,097
Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro
Dada Nexus, Bilibili And Other Big Stocks Moving Lower On Monday
30 Jan 23
U.S. stocks traded lower, with the Nasdaq Composite dropping over 100 points on Monday. Here are some big stocks recording losses in today’s session.
Orchestra BioMed Debuts As Nasdaq-Traded Company With Lead Programs Targeting Hypertension And Artery Disease And Novel Partnership-Enabled Business Model
27 Jan 23
Business combination with Health Sciences Acquisitions Corporation 2, a special purpose acquisition company sponsored by an affiliate of RTW Investments, LP, completed on January 26, 2023 The combination was

Press releases

From Benzinga Pro
Orchestra BioMed Debuts as Nasdaq-Traded Company with Lead Programs Targeting Hypertension and Artery Disease and Novel Partnership-Enabled Business Model
27 Jan 23
Business combination with Health Sciences Acquisitions Corporation 2, a special purpose acquisition company sponsored by an affiliate of RTW Investments, LP, completed on January 26, 2023 The combination was announced
Finsight
Resources
  • Knowledgebase
  • Log In
  • Register
Company
  • About
  • Contact
  • Solutions
Products
  • Deal Roadshow
  • DealVDR
  • Evercall
  • Finsight.com
CapEdge
  • Earnings Calendar
  • Earnings Transcripts
  • EDGAR Filing Screener
  • IPO Calendar
  • Compliance
  • Privacy
  • Security
  • Terms
AngelList LinkedIn